1. Overview
Malignant Pleural Mesothelioma (MPM) is an aggressive, locally invasive neoplasm arising from the mesothelial cells lining the pleural cavity. It represents the most common primary malignancy of the pleura, accounting for over 90% of all mesothelioma cases. MPM is causally linked to asbestos exposure in the vast majority of cases, characterized by a long latency period (typically 20–50 years), and carries a historically poor prognosis.
Despite advances in multimodal therapy, MPM remains a challenging disease to manage, requiring a coordinated, multidisciplinary approach involving thoracic surgeons, medical oncologists, radiation oncologists, radiologists, pathologists, and palliative care specialists.
A history of asbestos exposure—occupational, para-occupational (household contact), or environmental—is the single most important risk factor. However, a significant minority of patients (10–20%) report no known exposure.
2. Epidemiology & Risk Factors
Incidence & Demographics
| Parameter | Details |
|---|---|
| Global Incidence | ~30,000–35,000 new cases/year worldwide; rising in developing nations due to ongoing asbestos use. |
| Peak Incidence | Expected in Western Europe, Australia, and Japan around 2020–2030; declining in US/Scandinavia post-1980s bans. |
| Median Age at Diagnosis | 70–75 years. |
| Sex Distribution | Male : Female ratio ~ 4:1 to 5:1 (reflecting historical occupational exposure patterns). |
| Latency Period | Mean 35–40 years (Range: 15–60+ years). Risk does not diminish after exposure cessation. |
Etiology & Risk Factors
Primary Risk Factor: Asbestos Exposure
- Fiber Types: All commercial forms are carcinogenic.
- Amphiboles (Crocidolite > Amosite > Tremolite): Higher biopersistence, greater mesothelioma potency.
- Serpentine (Chrysotile): Lower potency but accounts for >90% of historical use; contamination with tremolite often drives risk.
- Dose-Response: Risk correlates with cumulative dose (fibers/mL-years), but no safe threshold has been established.
Other Established/Potential Risk Factors
- Ionizing Radiation: Therapeutic radiation to the chest (e.g., for lymphoma) increases risk after 15+ years latency.
- Erionite: A fibrous zeolite mineral (turkey, North Dakota, USA) with potency far exceeding asbestos.
- Genetic Predisposition: Germline BAP1 (BRCA1-associated protein 1) mutations cause a hereditary cancer syndrome (BAP1-TPDS) with high penetrance for MPM, uveal melanoma, RCC, and cutaneous tumors.
- Simian Virus 40 (SV40): Historical contaminant of polio vaccines (1955–1963); mechanistic role in human MPM remains controversial and unproven as a primary driver.
3. Pathology & Molecular Biology
Histological Subtypes (WHO Classification)
Accurate subtyping is mandatory as it dictates treatment eligibility and prognosis.
| Subtype | Frequency | Key Histologic Features | Prognosis | Treatment Implication |
|---|---|---|---|---|
| Epithelioid | 55–65% | Tubulopapular, solid, micropapillary, deciduoid patterns. Uniform cells, distinct borders. | Best (Median OS ~ 18–24 mo) | Eligible for aggressive multimodal therapy (Surgery + Chemo ± RT). |
| Sarcomatoid | 10–20% | Spindle cells, high mitotic activity, necrosis, storiform/whorled patterns. Mimics sarcoma. | Worst (Median OS ~ 6–10 mo) | Generally not surgical candidates; systemic therapy / clinical trials preferred. |
| Biphasic (Mixed) | 20–30% | Contains both epithelioid and sarcomatoid components (>10% of either). | Intermediate (Depends on % epithelioid) | Surgical eligibility depends on dominant component & resectability assessment. |
Diagnostic Pitfall:** *Desmoplastic mesothelioma (a sarcomatoid variant) is paucicellular with dense collagen; requires deep biopsy and extensive IHC to distinguish from fibrous pleuritis.
Immunohistochemistry (IHC) Panel
No single marker is 100% sensitive/specific. Diagnosis relies on a panel approach (Positive and Negative markers).
| Marker Category | Markers | Interpretation |
|---|---|---|
| Mesothelial (Positive) | Calretinin (Nuclear/Cytoplasmic), WT-1 (Nuclear), D2-40 (Podoplanin) (Membranous), Cytokeratin 5/6 (Cytoplasmic) | Support Mesothelioma. Loss of nuclear BAP1 supports malignancy. |
| Carcinoma (Negative) | Ber-EP4 (EpCAM), MOC-31, CEA (Carcinoembryonic Antigen), TTF-1 (Lung primary), Napsin A | Rule out Metastatic Adenocarcinoma. Must be negative. |
| Ancillary | BAP1 (Loss = Malignancy support), MTAP (Loss = CDKN2A deletion surrogate), p16 (CDKN2A) (Loss by FISH/IHC = Malignancy) | Distinguish Reactive vs. Neoplastic. Homozygous CDKN2A (p16) deletion by FISH is the gold standard genetic marker for malignancy. |
Key Molecular Alterations
- Tumor Suppressor Loss (Near Universal): CDKN2A (p16/INK4a – ~70-90%), NF2 (Merlin – ~40-50%), BAP1 (~60% epithelioid).
- Low Tumor Mutational Burden (TMB): Typically < 2 mut/Mb; limits immunotherapy efficacy as monotherapy.
- Actionable Targets (Rare): PI3K/AKT/mTOR pathway mutations, EGFR mutations (rare), ALK rearrangements (anecdotal).
4. Clinical Presentation
Common Symptoms (Insidious Onset)
- Dyspnea (90%): Due to pleural effusion, tumor encasement, or trapped lung.
- Pleuritic Chest Pain (60–70%): Sharp, localized; indicates chest wall invasion.
- Constitutional Symptoms: Weight loss, fatigue, night sweats, low-grade fever (paraneoplastic).
- Physical Exam: Dullness to percussion, decreased breath sounds, reduced tactile fremitus (effusion); fixed, stony dullness (trapped lung/tumor mass).
Uncommon / Late Presentations
- Hoarseness: Recurrent laryngeal nerve palsy (mediastinal involvement).
- Superior Vena Cava (SVC) Syndrome: Mediastinal nodal bulk.
- Horner’s Syndrome: Apical tumor extension (Pancoast-like).
- Hypoglycemia: Paraneoplastic secretion of IGF-II (large solitary fibrous tumors vs mesothelioma).
- Thrombocytosis / DVT/PE: Paraneoplastic hypercoagulability (Trousseau’s syndrome).
5. Diagnostic Workup
Imaging Strategy
| Modality | Role | Key Findings |
|---|---|---|
| Chest X-Ray (CXR) | Initial screening | Unilateral pleural effusion (often large), pleural thickening/nodularity, volume loss (hemithorax contraction). |
| Contrast-Enhanced CT Chest/Abdomen | Standard Staging | Nodular pleural thickening (>1 cm), mediastinal pleural involvement, interlobular fissure nodularity, chest wall invasion (rib destruction, extra-pleural fat stranding), diaphragmatic invasion, pericardial thickening, nodal stations, liver/adrenal mets. |
| MRI Chest | Problem-solving | Superior soft tissue contrast for chest wall, diaphragmatic, pericardial, or brachial plexus invasion. Useful if CT contrast contraindicated. |
| PET-CT (FDG) | Staging / Response | High sensitivity for nodal/metastatic disease (SUVmax usually > 2.5). False negatives: Small volume disease, sarcomatoid histology (lower FDG avidity), post-talc pleurodesis inflammation (False positive). |
| Ultrasound | Procedure guidance | Essential for safe thoracentesis/biopsy; loculations, diaphragmatic thickness. |
Tissue Diagnosis: The Critical Step
Cytology alone (thoracentesis fluid) has low sensitivity (~25–35%). Tissue biopsy is the standard.
| Procedure | Indication | Sensitivity | Complications |
|---|---|---|---|
| Image-Guided Core Needle Biopsy (CT/US) | First-line for accessible pleural-based lesions. | 85–95% (Epithelioid); Lower for Sarcomatoid. | Pneumothorax (10–15%), tract seeding (rare but reported). |
| Thoracoscopy (Medical/LATS/VATS) | Failed needle biopsy; Need for pleurodesis; Diagnostic uncertainty. | > 98% (Gold Standard). | Requires sedation/GA; empyema risk; port-site metastasis (prophylactic RT debated). |
| EBUS-TBNA / EUS-FNA | Mediastinal nodal staging (N2/N3). | High for nodal mets. | Does not diagnose primary pleural tumor. |
Tract Seeding Prophylaxis: Prophylactic radiotherapy to intervention tracts (21 Gy in 3 fractions) is controversial. Current guidelines (NCCN, ESMO) do not** routinely recommend it outside clinical trials, though it is practiced in some centers (especially UK).
6. Staging: TNM 8th Edition (AJCC/UICC)
Staging applies only to Epithelioid and Biphasic subtypes. Sarcomatoid is generally staged clinically but rarely treated surgically.
T Category (Primary Tumor)
- T1: Ipsilateral parietal pleura ± visceral pleura.
- T1a: Parietal only.
- T1b: Parietal + Visceral.
- T2: T1 features + Diaphragm or Lung parenchyma invasion.
- T3: Locally advanced but potentially resectable: Endothoracic fascia, Mediastinal fat, Single focus chest wall (rib), Pericardium (parietal), Internal mammary nodes.
- T4: Unresectable: Diffuse chest wall, Pericardium (visceral/myocardium), Trachea/Esophagus, Contralateral pleura, Mediastinal organs, Spine, Brachial plexus, Across diaphragm/peritoneum.
N Category (Regional Nodes)
- N0: No nodal mets.
- N1: Ipsilateral bronchial/hilar (Station 10-14).
- N2: Ipsilateral mediastinal/subcarinal (Station 1-9).
- N3: Contralateral mediastinal/hilar, Supraclavicular (Station 1, Supraclavicular).
M Category
- M0: No distant mets.
- M1: Distant mets (Contralateral lung, Liver, Bone, Brain, Distant nodes).
Stage Grouping (Simplified)
| Stage | T | N | M | Resectability Context |
|---|---|---|---|---|
| IA | T1a | N0 | M0 | Resectable |
| IB | T1b / T2 | N0 | M0 | Resectable |
| II | T3 | N0 | M0 | Borderline Resectable (Multidisciplinary review essential) |
| IIIA | T1-3 | N1 | M0 | Potentially Resectable (Induction therapy often used) |
| IIIB | T1-3 / T4 | N2 | M0 | Generally Unresectable (T4 or N2 = systemic therapy) |
| IV | Any T | N3 / Any N | M1 | Unresectable (Palliative systemic therapy) |
7. Management Principles
Treatment is stage- and histology-dependent. All cases must be discussed at a Multidisciplinary Team (MDT) Meeting with mesothelioma expertise.
Resectable Disease (Stages I–IIIA, Epithelioid/Biphasic)
Goal: Macroscopic Complete Resection (MCR) + Local Control + Systemic Control.
A. Neoadjuvant (Induction) Therapy
- Standard: Cisplatin + Pemetrexed (3–4 cycles).
- Evidence: Based on extrapolation from advanced disease data (EMPHACIS trial) and CheckMate 743 (immunotherapy). No Phase III trial proves neoadjuvant chemo improves OS over surgery alone, but it is standard practice to treat micromets and assess biology.
- Emerging: Neoadjuvant Nivolumab + Ipilimumab or Chemo + Immunotherapy (e.g., PRISM, INITIATE trials) showing high pathological response rates.
B. Surgical Options (Controversial / Selective)
| Procedure | Description | Mortality | Key Indication |
|---|---|---|---|
| Extended P/D (eP/D) | Resection of parietal/visceral pleura, diaphragm, pericardium WITHOUT lung resection. | 2–5% | Preferred by many centers. Preserves lung function; lower morbidity. |
| Extrapleural Pneumonectomy (EPP) | En bloc resection of lung, parietal/visceral pleura, diaphragm, pericardium + reconstruction. | 5–10%+ | Highly selected T3/T4 (chest wall/diaphragm) where lung cannot be spared. Falling out of favor due to MARS/SAKK trial data showing harm/no benefit. |
| Partial Pleurectomy / Debulking | Incomplete resection (R2). | Low | Palliative only (trapped lung, symptomatic effusion). Not curative intent. |
MARS 2 Trial (UK): Compared eP/D + Chemo vs Chemo alone. Result: No OS benefit for surgery; higher serious adverse events. Current Consensus: Surgery remains an option for highly selected patients in expert centers, but not standard of care** for all resectable patients. Shared decision-making is paramount.
C. Adjuvant Radiation Therapy
- Post-eP/D: Hemithoracic RT (50–54 Gy) standard to reduce local recurrence (high risk without RT).
- Post-EPP: Hemithoracic RT standard (historically 54 Gy).
- Technique: IMRT / VMAT / Proton Therapy essential to spare lung, heart, liver, esophagus, spinal cord.
- Timing: Usually 4–8 weeks post-op (after chemo recovery).
D. Adjuvant Systemic Therapy
- Standard: Completion of Cisplatin/Pemetrexed (total 4–6 cycles).
- Immunotherapy Maintenance: Nivolumab (CheckMate 743 subset) or Pembrolizumab (KEYNOTE-028/158) used off-label/guideline-preferred in some regions post-chemo, though Phase III adjuvant IO data (e.g., ATEMPT, MESOT-NET) pending.
Unresectable / Advanced Disease (Stage IIIB, IV, Sarcomatoid, Poor PS)
Goal: Symptom control, Quality of Life (QoL), Survival prolongation.
First-Line Systemic Therapy (Standard of Care)
| Regimen | Histology | Key Trial | Median OS | Key Toxicity |
|---|---|---|---|---|
| Nivolumab + Ipilimumab | All (Preferred for Non-Epithelioid) | CheckMate 743 | 18.1 mo (vs 14.1 Chemo) | Immune-related AEs (Hepatitis, Colitis, Pneumonitis, Endocrinopathies). Requires steroids/holds. |
| Cisplatin/Carboplatin + Pemetrexed | Epithelioid (Standard if IO contraindicated) | EMPHACIS / MAPS | ~14–16 mo | Myelosuppression, Nephrotoxicity (Cisplatin), Nausea, Fatigue. Mandatory: Folic acid + B12 + Dexamethasone premed. |
| Cisplatin/Carboplatin + Pemetrxed + Bevacizumab | Epithelioid (Selected, No cardiac/squamous hx) | MAPS | ~18.8 mo (vs 16.1) | Hypertension, Proteinuria, Bleeding, Fistula risk. Adds modest benefit. |
Biomarker Note: PD-L1 expression (TPS ≥ 1%) predicts better IO benefit, but Nivo/Ipi is approved regardless of PD-L1**. Sarcomatoid tumors derive the greatest relative benefit from dual IO vs chemo.
Second-Line & Subsequent Therapy
- No established standard.
- Options: Single-agent Pemetrexed (re-challenge if >6 mo break), Vinorelbine, Gemcitabine, Pembrolizumab/Nivolumab (if not used 1st line), Clinical Trials (ADCs, CAR-T, Targeted agents, Viral therapy).
- Tumor Treating Fields (TTFields) + Chemo: FDA approved (STELLAR trial) for unresectable MPM; modest OS benefit (18.2 vs 14.1 mo), high adherence burden (18 hrs/day), skin toxicity.
Palliative & Supportive Care (Integral at All Stages)
| Symptom / Issue | Intervention |
|---|---|
| Malignant Pleural Effusion | Tal c Pleurodesis (Graded Talc, 4-5g via VATS or slurry) – Gold standard. IPC (Indwelling Pleural Catheter) – First line for trapped lung / failed pleurodesis / home drainage preference. IPC + Talc (TIME2 trial) – Fastest symptom control. |
| Pain | WHO Analgesic Ladder; Intercostal Nerve Blocks / Neurolysis; Radiotherapy (30 Gy/10 fx or 20 Gy/5 fx) for chest wall invasion; Palliative care referral early. |
| Dyspnea | Opioids (low dose), Benzodiazepines (anxiety), Pulmonary Rehab, Fan therapy, Oxygen (if hypoxic). |
| Nutrition | Dietician input; Sarcopenia management (resistance exercise, protein supplementation). |
| Psychosocial | Mesothelioma specialist nurses; Legal/Compensation advice (Asbestos trusts); Advance Care Planning. |
8. Prognosis & Prognostic Factors
Survival Statistics (General Estimates)
- Overall Median OS: 12–18 months (Historical chemo); 18–22 months (Modern IO combinations).
- 5-Year OS: < 5% (Historical); ~10–15% (Selected surgical/MDT cohorts); ~23% (Nivo/Ipi 3-yr landmark CheckMate 743).
- Sarcomatoid: Median OS 6–9 months (Chemo); ~15 months (Nivo/Ipi).
Validated Prognostic Scores
| Score | Variables | Use Case |
|---|---|---|
| CALGB / EORTC | PS, WBC, Histology, Stage, LDH, Age | Baseline risk stratification (Clinical Trials). |
| Lent Score | Histology, Stage, PS, LDH, Platelets, Age | Simpler clinical tool. |
| mPPS (Modified PPS) | PS, Primary Site, Mets, Albumin, LDH | Palliative care / Hospice eligibility. |
Key Individual Prognostic Factors
- Favorable: Epithelioid histology, Female sex, Age < 70, ECOG PS 0–1, Normal LDH, Normal Platelets, Early Stage (I/II), BAP1 loss (paradoxically better differentiation/immunogenicity?), PD-L1 high (for IO).
- Unfavorable: Sarcomatoid/Biphasic (high %), Male, Age > 75, ECOG PS ≥ 2, Elevated LDH, Thrombocytosis (>400k), Leukocytosis, N2/N3 nodes, M1 disease, CDKN2A homozygous deletion (often), High NLR (Neutrophil-to-Lymphocyte Ratio).
9. Follow-Up & Survivorship
- Frequency: Every 3–4 months for first 2 years; Every 6 months years 3–5; Annually thereafter.
- Imaging: Contrast-Enhanced CT Chest/Abdomen (Standard). PET-CT reserved for suspected recurrence equivocal on CT.
- Surveillance for Second Primaries: Increased risk of lung cancer (asbestos synergy with smoking), renal cell carcinoma (BAP1 carriers), skin cancers.
- Late Toxicity Monitoring: Cardiac function (Anthracyclines/Radiation), Pulmonary function (Post-surgery/RT), Renal function (Cisplatin), Endocrine (IO-related thyroid/adrenal insufficiency), Neuropathy.
10. Prevention & Screening
Primary Prevention
- Asbestos Ban: Complete ban on mining, import, and use (achieved in >60 countries).
- Abatement Regulations: Strict engineering controls, PPE, licensed removal contractors for existing buildings (schools, hospitals, homes).
- Smoking Cessation: Critical—Asbestos + Smoking = Synergistic risk for Lung Cancer (multiplicative), though not for Mesothelioma (additive/independent).
Screening / Early Detection
- No general population screening recommended.
- High-Risk Cohorts (Asbestos workers, BAP1 carriers): Annual Low-Dose CT (LDCT) for Lung Cancer screening (per USPSTF/NCCN criteria) may detect early pleural changes, but no mortality benefit proven for MPM screening.
- Biomarkers: Soluble Mesothelin-Related Peptides (SMRP / Mesomark), Fibulin-3, MicroRNAs. Not validated for screening/diagnosis. Used only for monitoring response in known disease.
11. Emerging Therapies & Clinical Trials
Patients should be encouraged to enroll in clinical trials at all stages.
| Therapeutic Class | Examples / Targets | Status |
|---|---|---|
| Antibody-Drug Conjugates (ADCs) | Anvetuximab Ravtansine (Mesothelin), Sacituzumab Govitecan (TROP2) | Phase II/III (e.g., MESOTHELIOMA, MATTERHORN). Promising response rates. |
| CAR-T / TCR Therapy | Mesothelin-targeted CAR-T, WT-1 TCR | Early Phase (safety/feasibility); On-target off-tumor toxicity challenge. |
| Epigenetic Modulators | EZH2 inhibitors (Tazemetostat – BAP1 loss context), HDAC inhibitors | Phase II; Modest single agent activity, combos explored. |
| FAK Inhibitors | Defactinib | Failed Phase III (COMMAND) as maintenance; combos ongoing. |
| Viral Therapy | ONCOS-102 (Adenovirus + GM-CSF) + Chemo/IO | Phase II/III; Immune activation in “cold” tumors. |
| TTFields + IO | NovoTTF-100L + Pembrolizumab | Phase II (LUNAR trial); Feasibility demonstrated. |
12. Patient Resources & Support
- Mesothelioma Applied Research Foundation (MARF / CureMeso): Research funding, patient navigation, support groups.
- Asbestos Disease Awareness Organization (ADAO): Advocacy, education, community.
- National Cancer Institute (NCI) / Cancer.gov: PDQ summaries, clinical trial search.
- Mesothelioma UK / British Lung Foundation: Specialist nursing, benefits advice (UK specific).
- Legal/Compensation: Specialized asbestos litigation firms (statutes of limitations apply).
References (Harvard Style)
- American Joint Committee on Cancer (2017) AJCC Cancer Staging Manual. 8th edn. Chicago: Springer.
- Baas, P. et al. (2021) ‘First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial’, The Lancet, 397(10272), pp. 375–386.
- Bibby, A.C. et al. (2020) ‘Surgery for malignant pleural mesothelioma: a systematic review and meta-analysis’, European Respiratory Review, 29(155), p. 190100.
- Bradley, A. et al. (MARS 2 Trial Investigators) (2023) ‘Surgery versus no surgery for malignant pleural mesothelioma (MARS 2): an open-label, randomised, controlled, multicentre trial’, The Lancet Respiratory Medicine, 11(5), pp. 425–436.
- Bryne, M. et al. (2023) ‘Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 34(1), pp. 20–34.
- Hanna, N.H. et al. (2024) ‘NCCN Guidelines Version 2.2024: Malignant Pleural Mesothelioma’, National Comprehensive Cancer Network. Available at: https://www.nccn.org (Accessed: [Current Date]).
- Hoda, M.A. et al. (2022) ‘Tumor Treating Fields with chemotherapy for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, randomised, controlled, phase 2 trial’, The Lancet Oncology, 23(2), pp. 239–248.
- Kindler, H.L. et al. (2012) ‘Bevacizumab plus chemotherapy for malignant pleural mesothelioma (MAPS): a randomised, controlled, phase 3 trial’, The Lancet, 379(9828), pp. 1912–1920.
- Nowak, A.K. et al. (2021) ‘Nivolumab plus ipilimumab in malignant pleural mesothelioma: 3-year update from CheckMate 743’, Journal of Thoracic Oncology, 16(10), pp. 1732–1742.
- Robinson, B.W.S. and Lake, R.A. (2023) ‘Malignant Mesothelioma’, in DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 12th edn. Philadelphia: Wolters Kluwer, pp. 890–915.
- Scherpereel, A. et al. (2019) ‘Guidelines for the diagnosis and treatment of malignant pleural mesothelioma: 2019 update’, European Respiratory Journal, 53(1), p. 1800399.
- Travis, W.D. et al. (2021) WHO Classification of Tumours: Thoracic Tumours. 5th edn. Lyon: IARC Press.
- Vogelzang, N.J. et al. (2003) ‘Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma’, Journal of Clinical Oncology, 21(14), pp. 2636–2644.
- Wu, X. et al. (2023) ‘Germline BAP1 mutations and the risk of malignant mesothelioma: a systematic review and meta-analysis’, Journal of Thoracic Oncology, 18(4), pp. 489–500.
- Zalcman, G. et al. (2016) ‘Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial’, The Lancet, 387(10026), pp. 1405–1414.
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Clinical decisions must be made by a qualified multidisciplinary team based on individual patient assessment. Guidelines and drug approvals vary by jurisdiction and update frequently.